Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
News
CHOLESTASIS
NewsMaternal liver damage markers can predict twin pregnancy outcomes
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…
FATTY LIVER DISEASE
NewsNorUDCA becomes first MASLD therapy approved in India
India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
ALAGILLE SYNDROME
NewsAlagille syndrome symptoms vary by gene mutation, study finds
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1 gene or the NOTCH2 gene,…
HEPATITIS
NewsDosing begins in Phase 2 trial of ALG-000184 for hepatitis B
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…
CHOLANGITIS
NewsPSC raises colorectal cancer risk even without IBD
People with primary sclerosing cholangitis (PSC) have a six times higher risk of cancer affecting the large intestine or rectum, and that risk remained…
A new artificial intelligence (AI) algorithm can help identify babies with genetic forms of cholestasis, including progressive familial intrahepatic cholestasis (PFIC), using data from…
FATTY LIVER DISEASE
NewsFatty liver disease linked to projected rise in liver cancer
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
BILIARY ATRESIA
NewsStudy finds a new player behind liver scarring in biliary atresia
A new study has uncovered a key mechanism behind the liver scarring seen in biliary atresia (BA), a rare liver disease in infants. Two…
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…
Recent Posts
- World Liver Day promotes small habits that can yield big health gains
- FDA puts pevifoscorvir sodium for hepatitis B on fast track
- Off-label fenofibrate improves liver health in PBC patients: Study
- Gestational diabetes boosts risk of liver issue during pregnancy: Study
- Learning how to let go of worry isn’t easy as an Alagille parent